Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06367270
Other study ID # UW 23-361
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date September 1, 2023
Est. completion date August 31, 2027

Study information

Verified date April 2024
Source The University of Hong Kong
Contact Ian WONG, Dr.
Phone +852 2255 4774
Email iyhwong@hku.hk
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is a novel minimally invasive drug delivery system for patients with peritoneal metastases (PM). It has been considered as a safe and feasible palliative treatment alternative proven by previous phase I studies. Currently available evidence on feasibility, efficacy and tolerability in Asian populations is limited. In this open-label, single-arm, monocentric clinical trial, investigators aim to evaluate the therapeutic efficacy and complications of PIPAC with oxaliplatin as an alternative on patients of unresectable colorectal cancer with PM and doxorubicin and cisplatin on patients of unresectable gastric and pancreatic cancers with PM. Alternative regimen can be considered multidisciplinary tumour board meeting. Patients will be recruited according to the inclusion criteria and treated for 3 cycles of PIPAC and concurrent systemic chemotherapy. The goal was to repeat PIPAC every 6-8 weeks for at least three procedures, and the delay of the systemic chemotherapy is 2 weeks before and after each PIPAC procedure. If PM was considered to become resectable during PIPAC, patients were discussed at the multidisciplinary tumour board for curative intent cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). The primary outcome is the clinical benefit rate (CBR), measured by an independent radiologist according to Response Evaluation Criteria In Solid Tumors (RECIST) and Peritoneal Cancer Index (PCI) assessed by laparoscopy and histopathological tumour response evaluated by pathologists blinded to clinical outcomes. Key secondary outcomes include the major and minor treatment-related adverse events according to the Common Terminology Criteria for Adverse Events (CTACE) up to 4 weeks after the treatment, Cytological tumour response of peritoneal lavage or ascites, treatment-related characteristics, hospital stay, progression-free survival, overall survival and readmission rate. The proposed study duration is 3 years from the start date and the estimated sample size is 51 according to centre capacity.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date August 31, 2027
Est. primary completion date August 31, 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. =18 years of old; 2. WHO performance of status 0-1; 3. Histologically or cytologically proven PM of a gastric, pancreatic or colorectal carcinoma; 4. Treatment naïve patients as first-line treatment; 5. Progression on or intolerance to first-line systemic chemotherapy as second-line treatment; 6. No symptoms of gastrointestinal obstruction; 7. No contraindications for the planned systemic therapy or laparoscopy; 8. No previous PIPAC/IP/HIPEC; 9. No other concurrent malignancies or any other malignancy within 6 months prior to enrolment; 10. Able to give written informed consent. Exclusion Criteria: 1. A history of allergic reaction to platinum containing compounds or doxorubicin; 2. Pregnant or breastfeeding; 3. Any extra-peritoneal metastases; 4. Renal impairment, defined as GFR less than 40 mL/min; 5. Impaired liver function defined as bilirubin over 1.5 × UNL; 6. Inadequate haematological function - Leucocyte < 3.00 × 109/L - Absolute neutrophil counts < 1.50 × 109/L - Platelet < 100 × 109/L

Study Design


Intervention

Drug:
Pressured Intraperitoneal Aerosol Chemotherapy
PIPAC cycles will be scheduled every 6-8 weeks and 2 weeks after the last systemic chemotherapy administration. The bidirectional program for the combination of intraperitoneal and systemic chemotherapy is designed as follows: systemic chemotherapy followed by PIPAC two weeks later, followed by a one-week interval, and then systemic chemotherapy once again until three PIPAC cycles have been completed. Up to a one-week delay in returning to systemic chemotherapy after PIPAC and vice versa were considered acceptable. Systemic drug choice was based on previous chemotherapy exposure and the medical oncologists' decision. The study ends after the 3rd cycle of PIPAC.

Locations

Country Name City State
Hong Kong Queen Mary Hospital Hong Kong

Sponsors (1)

Lead Sponsor Collaborator
The University of Hong Kong

Country where clinical trial is conducted

Hong Kong, 

Outcome

Type Measure Description Time frame Safety issue
Primary Clinical benefit rate (CBR) Clinical benefit rate (CBR) according to Response Evaluation Criteria In Solid Tumors (RECIST). At the end of Cycle 3 (each cycle is 6 to 8 weeks)
See also
  Status Clinical Trial Phase
Recruiting NCT03422432 - Prophylactic HIPEC for Colorectal Cancers at High Risk of Developing Peritoneal Metastases N/A
Not yet recruiting NCT06295094 - The Efficacy of PIPAC and Minimally Invasive Radical Resection in High-risk Gastric Cancer Patients. Phase 2
Recruiting NCT05056389 - Normothermic Intraperitoneal Chemotherapy - Long Term in Peritoneal Metastases From Colorectal Cancer (NIPEC-OXA) Phase 1
Withdrawn NCT03682744 - CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites (IPC) Phase 1
Recruiting NCT05623787 - Diagnostic Value of Diffusion-weighted Magnetic Resonance in High-risk Colorectal and Appendiceal Neoplasms N/A
Not yet recruiting NCT05095467 - HIPEC-AS in Patients With Peritoneal Metastasis of the Stomach or Esophagogastric Junction Phase 2
Completed NCT04083547 - Circulating Tumour Cells in Patients With Peritoneal Metastases
Recruiting NCT06216561 - Intraperitoneal LSTA1 in CRS-HIPEC Phase 1
Recruiting NCT05277766 - Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis From Gastrointestinal Cancer Phase 1
Not yet recruiting NCT05318794 - Neoadjuvant Systemic and Peritoneal Chemotherapy for Advanced Gastric Cancer Phase 2
Completed NCT05665257 - Feasibility of Preoperative Inspiratory Muscle Training for Patients With Peritoneal Metastases N/A
Terminated NCT05581719 - A Phase 1/2a Study Evaluating Allocetra-OTS as Monotherapy or in Combination With Anti-PD-1 Therapy for the Treatment of Advanced Solid Tumor Malignancy Phase 1/Phase 2
Recruiting NCT05379790 - Concomitant Intraperitoneal and Systemic Chemotherapy in Patients With Extensive Peritoneal Carcinomatosis of Gastric Origin Phase 1
Recruiting NCT04956068 - PIPAC for Peritoneal Metastases Phase 1
Recruiting NCT05204173 - Efficacy and Safety of Sintilimab Combined Intraperitoneal and Intravenous Paclitaxel Plus Oral S-1 in Gastric Cancer Patients With Peritoneal Metastasis Phase 2
Recruiting NCT04861558 - Efficacy of Hyperthermic Intraperitoneal Chemotherapy Phase 3
Recruiting NCT05340569 - Diagnostic Value of DWI-MRI for Detection of Peritoneal Metastases in High-risk Pancreatic Ductal Adenocarcinoma. N/A
Recruiting NCT03834272 - Feasibility of the LUM Imaging System for Peritoneal Surface Malignancies Phase 1/Phase 2
Completed NCT03733184 - Development of an IDEAL Framework to Standardise Cytoreductive Surgery for Colorectal Peritoneal Metastases
Recruiting NCT05755672 - On-treatment Biomarkers in Metastatic Colorectal Cancer for Life